TOP TEN perturbations for 1552808_at (Homo sapiens)
Organism: Homo sapiens
Gene: 1552808_at
Selected probe(set): 229585_at
Platform: Affymetrix Human Genome U133 Plus 2.0 Array
Expression of 1552808_at (229585_at) across 6537 perturbations tested by GENEVESTIGATOR:
connective/soft tissue cancer study 1 (PDX; connective and soft tissue, synovial sarcoma, spindle cell; primary) / connective/soft tissue cancer study 1 (PDX; connective and soft tissue, liposarcoma, NOS; primary)
Relative Expression (log2-ratio):4.2033997Number of Samples:6 / 2
| Experimental | connective/soft tissue cancer study 1 (PDX; connective and soft tissue, synovial sarcoma, spindle cell; primary) |
| Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary connective and soft tissue, synovial sarcoma, spindle cell of the soft tissue (subcutaneously implanted). | |
| Control | connective/soft tissue cancer study 1 (PDX; connective and soft tissue, liposarcoma, NOS; primary) |
| Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary connective and soft tissue, liposarcoma, NOS of the soft tissue (subcutaneously implanted). |
renal cell carcinoma study 10 (PDX; clear cell adenocarcinoma, NOS; metastatic) / renal cell carcinoma study 10 (PDX; clear cell adenocarcinoma, NOS; primary)
Relative Expression (log2-ratio):4.0588923Number of Samples:2 / 18
| Experimental | renal cell carcinoma study 10 (PDX; clear cell adenocarcinoma, NOS; metastatic) |
| Patient-derived xenograft (PDX) samples generated in female athymic nude mice from a metastasis of patients with primary clear cell adenocarcinoma, NOS of the kidney (subcutaneously implanted). Metastatic site of patient tumor sample is not reported. | |
| Control | renal cell carcinoma study 10 (PDX; clear cell adenocarcinoma, NOS; primary) |
| Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary clear cell adenocarcinoma, NOS of the kidney (subcutaneously implanted). |
bone cancer study 1 (PDX; chondroblastic osteosarcoma; primary) / bone cancer study 1 (PDX; myxoid chondrosarcoma; primary)
Relative Expression (log2-ratio):-3.9044476Number of Samples:2 / 2
| Experimental | bone cancer study 1 (PDX; chondroblastic osteosarcoma; primary) |
| Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary chondroblastic osteosarcoma of the bone (subcutaneously implanted). | |
| Control | bone cancer study 1 (PDX; myxoid chondrosarcoma; primary) |
| Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary myxoid chondrosarcoma of the bone (subcutaneously implanted). |
glioma study 16 (LN-229) / normal astrocyte sample
Relative Expression (log2-ratio):-3.7979813Number of Samples:2 / 3
| Experimental | glioma study 16 (LN-229) |
| Human glioma cell line LN229 was cultured in DMEM supplemented with 10% FCS (fetal calf serum) and antibiotics at 37°C and 5% CO2. | |
| Control | normal astrocyte sample |
| Normal brain astrocytes. Clonetics normal human astrocytes (NHA) from Cambrex (primary-derived cultures) and cultured according to the manufacturer's recommendations. |
stem cell differentiation study 47 (BMP-2; TGFb; IBMX; 7d) / stem cell differentiation study 47 (0d)
Relative Expression (log2-ratio):-3.786045Number of Samples:3 / 6
| Experimental | stem cell differentiation study 47 (BMP-2; TGFb; IBMX; 7d) |
| Bone marrow-derived mesenchymal stem cell line (MSC) differentiated for 7 days in the presence of bone morphogenetic protein 2 (BMP-2, 50ng/ml), transforming growth factor beta (TGFb, 5 ng/ml) and 3-isobutyl-1-methylxanthine (IBMX, 250 μM). Cells were propagated for not more than five passages in mesenchymal stem cell growth medium, at 37 °C and in a humidified atmosphere containing 7.5 % CO2. MSCs were incubated for 24 hours in proliferation medium (PM, high glucose DMEM, 10 % FBS, 100 U/ml penicillin, and 100 μg/ml streptomycin). Subsequently PMCs were differentiated for 7 days in differentiation medium (consisting of PM with 10EXP(-6)M dexamethasone, 10 μg/ml insulin, 10EXP(-7) M rosiglitazone, 50 ng/ml BMP-2, 5 ng/ml TGFb, 250 μM IBMX), and harvested. Samples are biological replicates. Normal bone marrow was obtained from 3 healthy donors (5F0138, 6F4085, 7F3458). | |
| Control | stem cell differentiation study 47 (0d) |
| Undifferentiated bone marrow-derived mesenchymal stem cell line (MSC) without any treatment. Cells were propagated for not more than five passages in mesenchymal stem cell growth medium, at 37 °C and in a humidified atmosphere containing 7.5 % CO2. MSCs were incubated for 24 hours in proliferation medium (high glucose DMEM, 10 % FBS, 100 U/ml penicillin, and 100 μg/ml streptomycin) and harvested. Samples are biological replicates. Normal bone marrow was obtained from 3 healthy donors (5F0138, 6F4085, 7F3458). |
bone cancer study 1 (PDX; chondrosarcoma, NOS; primary) / bone cancer study 1 (PDX; myxoid chondrosarcoma; primary)
Relative Expression (log2-ratio):-3.7628498Number of Samples:2 / 2
| Experimental | bone cancer study 1 (PDX; chondrosarcoma, NOS; primary) |
| Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary chondrosarcoma, NOS of the bone (subcutaneously implanted). | |
| Control | bone cancer study 1 (PDX; myxoid chondrosarcoma; primary) |
| Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary myxoid chondrosarcoma of the bone (subcutaneously implanted). |
connective/soft tissue cancer study 1 (PDX; connective and soft tissue, synovial sarcoma, spindle cell; primary) / connective/soft tissue cancer study 1 (PDX; connective and soft tissue, malignant peripheral nerve sheath tumor; primary)
Relative Expression (log2-ratio):3.735364Number of Samples:6 / 3
| Experimental | connective/soft tissue cancer study 1 (PDX; connective and soft tissue, synovial sarcoma, spindle cell; primary) |
| Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary connective and soft tissue, synovial sarcoma, spindle cell of the soft tissue (subcutaneously implanted). | |
| Control | connective/soft tissue cancer study 1 (PDX; connective and soft tissue, malignant peripheral nerve sheath tumor; primary) |
| Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary connective and soft tissue, malignant peripheral nerve sheath tumor of the soft tissue (subcutaneously implanted). |
stem cell differentiation study 47 (BMP-2; TGFb; IBMX; 2d) / stem cell differentiation study 47 (0d)
Relative Expression (log2-ratio):-3.6280794Number of Samples:3 / 6
| Experimental | stem cell differentiation study 47 (BMP-2; TGFb; IBMX; 2d) |
| Bone marrow-derived mesenchymal stem cell line (MSC) differentiated for 2 days in the presence of bone morphogenetic protein 2 (BMP-2, 50ng/ml), transforming growth factor beta (TGFb, 5 ng/ml) and 3-isobutyl-1-methylxanthine (IBMX, 250 μM). Cells were propagated for not more than five passages in mesenchymal stem cell growth medium, at 37 °C and in a humidified atmosphere containing 7.5 % CO2. MSCs were incubated for 24 hours in proliferation medium (PM, high glucose DMEM, 10 % FBS, 100 U/ml penicillin, and 100 μg/ml streptomycin). Subsequently PMCs were differentiated for 2 days in differentiation medium (consisting of PM with 10EXP(-6)M dexamethasone, 10 μg/ml insulin, 10EXP(-7) M rosiglitazone, 50 ng/ml BMP-2, 5 ng/ml TGFb, 250 μM IBMX), and harvested. Samples are biological replicates. Normal bone marrow was obtained from 3 healthy donors (5F0138, 6F4085, 7F3458). | |
| Control | stem cell differentiation study 47 (0d) |
| Undifferentiated bone marrow-derived mesenchymal stem cell line (MSC) without any treatment. Cells were propagated for not more than five passages in mesenchymal stem cell growth medium, at 37 °C and in a humidified atmosphere containing 7.5 % CO2. MSCs were incubated for 24 hours in proliferation medium (high glucose DMEM, 10 % FBS, 100 U/ml penicillin, and 100 μg/ml streptomycin) and harvested. Samples are biological replicates. Normal bone marrow was obtained from 3 healthy donors (5F0138, 6F4085, 7F3458). |
connective/soft tissue cancer study 1 (PDX; connective and soft tissue, malignant peripheral nerve sheath tumor; primary) / connective/soft tissue cancer study 1 (PDX; connective and soft tissue, fibromyxosarcoma; primary)
Relative Expression (log2-ratio):-3.6168795Number of Samples:3 / 5
| Experimental | connective/soft tissue cancer study 1 (PDX; connective and soft tissue, malignant peripheral nerve sheath tumor; primary) |
| Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary connective and soft tissue, malignant peripheral nerve sheath tumor of the soft tissue (subcutaneously implanted). | |
| Control | connective/soft tissue cancer study 1 (PDX; connective and soft tissue, fibromyxosarcoma; primary) |
| Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary connective and soft tissue, fibromyxosarcoma of the soft tissue (subcutaneously implanted). |
stem cell differentiation study 47 (BMP-2; TGFb; 7d) / stem cell differentiation study 47 (0d)
Relative Expression (log2-ratio):-3.614914Number of Samples:3 / 6
| Experimental | stem cell differentiation study 47 (BMP-2; TGFb; 7d) |
| Bone marrow-derived mesenchymal stem cell line (MSC) differentiated for 7 days in the presence of bone morphogenetic protein 2 (BMP-2, 50ng/ml) and transforming growth factor beta (TGFb, 5 ng/ml). Cells were propagated for not more than five passages in mesenchymal stem cell growth medium, at 37 °C and in a humidified atmosphere containing 7.5 % CO2. MSCs were incubated for 24 hours in proliferation medium (PM, high glucose DMEM, 10 % FBS, 100 U/ml penicillin, and 100 μg/ml streptomycin). Subsequently PMCs were differentiated for 7 days in differentiation medium (consisting of PM with 10EXP(-6)M dexamethasone, 10 μg/ml insulin, 10EXP(-7) M rosiglitazone, 50 ng/ml BMP-2, 5 ng/ml TGFb), and harvested. Samples are biological replicates. Normal bone marrow was obtained from 3 healthy donors (5F0138, 6F4085, 7F3458). | |
| Control | stem cell differentiation study 47 (0d) |
| Undifferentiated bone marrow-derived mesenchymal stem cell line (MSC) without any treatment. Cells were propagated for not more than five passages in mesenchymal stem cell growth medium, at 37 °C and in a humidified atmosphere containing 7.5 % CO2. MSCs were incubated for 24 hours in proliferation medium (high glucose DMEM, 10 % FBS, 100 U/ml penicillin, and 100 μg/ml streptomycin) and harvested. Samples are biological replicates. Normal bone marrow was obtained from 3 healthy donors (5F0138, 6F4085, 7F3458). |